Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$31.20 +0.74%

+$0.18 today

Market cap
$1.71B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 0.71M

Average 0.84M

MAZE Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

Maze Therapeutics, Inc.NASDAQ: MAZE

Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other current liabilities falls 25.5% from a year ago

Other current liabilities stood at $5.42M at the end of Q1 FY2026, down 25.5% from a year earlier and down 50.1% from the prior quarter. Over 3 fiscal years it compounded at +13.2% a year.

Context

  • Other current liabilities amounted to 1.3% of total assets at the end of Q1 FY2026, down 0.9 pp from a year earlier.
  • Other current liabilities increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether other current liabilities keeps falling in the next quarterly balance sheet after a -25.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.42M-50.1% QoQ
Last fiscal yearDec 2025
$10.85M+80.3% YoY
Year agoMar 2025
$7.27M-25.5% since
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.5%——
1 year+80.3%——
3-year CAGR+13.2%——
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
10.85M USD
Year-over-year change
+80.3%
3-year CAGR
+13.2%

Other Current Liabilities vs competitors

How MAZE compares with its peers on the latest reported figures

  • Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -25.5% is the 6th highest of 8, against a peer median of +30.9%.
  • Other current liabilities amounts to 1.3% of total assets for MAZE, versus a peer median of 3.3%.
MAZE Competitors
Other Current Liabilities for MAZE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PTCTPTC Therapeutics, Inc.Jun 2026$473.08M USD+31.8%+17.1%14.6%
TVTXTravere Therapeutics, Inc.Sep 2026$204.6M USD+521.1%-2.3%24.1%
SEPNSepterna, Inc.Sep 2026$26.4M USD-57.2%+51.2%4.3%
ARDXArdelyx, Inc.Mar 2026$9.38M USD+30.9%+87.7%1.9%
IVAInventiva S.A.Dec 2025€8.29M EUR-88.7%+53.8%3.3%
MAZEMaze Therapeutics, Inc.Mar 2026$5.42M USD-25.5%+13.2%1.3%
DMACDiaMedica Therapeutics Inc.Mar 2026$741K USD+117.3%+27.4%1.4%
BIOABioAge Labs, Inc.Mar 2026$714K USD+28.0%+179.7%0.2%
Peer median (excluding MAZE) —+30.9%+51.2%3.3%

Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents99.92M29.16M196.81M189.25M
Short-term Investments000152.67M
Net Receivables0000
Inventory0000
Other Current Assets6.23M4.95M4.86M7.8M
Total Current Assets106.15M34.11M201.67M349.72M
Property, Plant & Equipment (Net)41.23M34.98M29.92M25.16M
Goodwill0000
Intangible Assets0000
Long-term Investments1.21M1.09M1.09M18.11M
Tax Assets0000
Other Non-current Assets1.37M1.32M7.87M4.14M
Total Non-current Assets43.81M37.39M38.87M47.41M
Total Assets149.96M71.5M240.54M397.13M
Account Payables1.59M2.02M1.94M1.79M
Short-term Debt0000
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities7.49M2.93M6.02M10.85M
Total Current Liabilities20.78M16.32M20.67M22.56M
Long-term Debt020.08M00
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities01969K1.09M
Total Non-current Liabilities27.73M45.13M22.97M19.61M
Total Liabilities48.51M61.45M43.64M42.16M
Common Stock21K22K2K49K
Retained Earnings(295.27M)(395.69M)(358.43M)(489.55M)
Accumulated OCI000110K
Other Stockholders Equity0000
Minority Interest0000
Total Equity101.44M10.05M196.9M354.97M
Total Debt32.06M49.62M26.63M23.31M
Net Debt(67.86M)20.47M(170.18M)(165.94M)

Maze Therapeutics, Inc.

NASDAQ:MAZE

Intrinsic Alpha fair value

Locked

Current Price

$31.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.